Garcia-Gutierrez, E., Narbad, A
PlexusDx's precision-wellness approach recognizes that formulation choicesublingual versus injectableshould align not only with patient preference but also with individual metabolic biomarkers and genetic predispositions in GLP-1 and GIP signaling pathways
Other drugs in the pipeline for FDA approval in the second half of 2023 Eli Lilly's donanemab (A mAb/Alzheimer's) MSD's sotatercept As these rare disease research breakthroughs begin to be approved one by one, the need for unmet therapeutic areas is expected to gradually decrease
Tirzepatide is a dual GIP/GLP-1 receptor agonist, sold as Mounjaro (type 2 diabetes) and Zepbound (chronic weight management)
Regarding amphetamine, GLP-1 receptor activation has been observed to reduce amphetamine-induced conditioned place preference and locomotor activity in animal models
Overall, GLP-1 RAs showed a trend toward a reduction in all-cause mortality
